CD274 and neoplasm: A blood sample specimen suffices to evaluate many proposed proxy biomarkers, such as exosomes carrying PD-L1 mRNA or proteins (PD-L1+ exosomes), soluble PD-L1, or PD-L1+ circulating tumor cells [21,149].